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ABSTRACT
Natural dengue virus (DENV) infection in humans induces antibodies (Abs) that neutralize the serotype of infection in a potent
and type-specific manner; however, most Abs generated in response to infection are serotype cross-reactive and poorly neutraliz-
ing. Such cross-reactive Abs may enhance disease during subsequent infection with a virus of a different DENV serotype. Previ-
ous screening assays for DENV-specific human B cells and antibodies, using viral and recombinant antigens, mainly led to the
isolation of dominant nonneutralizing B cell clones. To improve upon our ability to recover and study rare but durable and po-
tently neutralizing DENV-specific Abs, we isolated human DENV-specific B cells by using a primary screen of binding to live
virus, followed by a secondary screen with a high-throughput, flow cytometry-based neutralization assay to identify DENV-spe-
cific B cell lines prior to generation of hybridomas. Using this strategy, we identified several new classes of serotype-specific and
serotype-cross-neutralizing anti-DENV monoclonal Abs (MAbs), including ultrapotent inhibitory antibodies with neutralizing
activity concentrations of <10 ng/ml. We isolated serotype-specific neutralizing Abs that target diverse regions of the E protein,
including epitopes present only on the intact, fully assembled viral particle. We also isolated a number of serotype-cross-neutral-
izing MAbs, most of which recognized a region in E protein domain I/II containing the fusion loop. These data provide insights
into targets of the protective Ab-mediated immune response to natural DENV infection, which will prove valuable in the design
and testing of new experimental DENV vaccines.
IMPORTANCE
Dengue virus infection is one of the most common mosquito-borne diseases and occurs in most countries of the world. Infection
of humans with dengue virus induces a small number of antibodies that inhibit the infecting strain but also induces a large num-
ber of antibodies that can bind but do not inhibit dengue virus strains of other serotypes. We used a focused screening strategy
to discover a large number of rare potently inhibiting antibodies, and we mapped the regions on the virus that were recognized
by such antibodies. Our studies revealed that humans have the potential to generate very potent antibodies directed to diverse
regions of the dengue virus surface protein. These studies provide important new information about protection from dengue
virus infection that will be useful in the design and testing of new experimental dengue vaccines for humans.
The range of dengue viruses (DENVs) has continued to expand,with DENVs causing an estimated 390 million infections in
2010, and the incidence of the most severe form of dengue disease
is on a steep rise (1, 2). The immunopathogenic mechanisms un-
derlying severe dengue disease are not completely understood, but
there are a plethora of data consistent with a model of antibody
(Ab)-mediated enhanced replication of DENV in cells bearing Ab
Fc receptors. Serotype-cross-reactive Abs induced following pri-
mary DENV infection bind to DENVs of heterologous types, but
they exhibit low potency for those serotypes in neutralization as-
says and do not protect against infection caused by the different
serotypes. In fact, these Abs are thought to form nonneutralized
antigen-Ab complexes that can allow the virus to enter cells ex-
pressing Fc receptors more efficiently, leading to increased viral
replication and, ultimately, worse disease. This process, known as
Ab-dependent enhancement (ADE) of infection, has been studied
extensively using human immune sera and human monoclonal
Abs (MAbs) in cell culture or animal models (3, 4).
DENVs are members of the Flaviviridae family that have pseu-
doicosahedral symmetry, displaying 180 copies of the envelope
(E) glycoprotein and of the premembrane/membrane (prM/M)
protein in the lipid bilayer membrane. There are three principal
domains that make up the immunodominant E glycoprotein
monomer, designated E domain I (EDI), EDII, and EDIII. Exten-
sive mapping studies of epitopes recognized by potently neutral-
izing mouse MAbs have identified several hot spots on all three
domains of the E protein. The most potent type-specific murine
neutralizing Abs have been shown to bind a region on the lateral
surface of the recombinant E protein DIII (5–9). As a result of
these studies, considerable previous efforts focused on EDIII for
possible use as a vaccine target. DENVs replicate poorly in mice,
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and recent studies suggest that the immunodominant regions rec-
ognized by experimentally inoculated mice and naturally infected
humans may differ (10).
A comprehensive understanding of the locations of antigenic
sites targeted by the protective human Ab response and the sites
responsible for the development of potentially harmful infection-
enhancing Abs is of critical importance. This topic has been an
area of intense investigation, with recent results beginning to shed
light on the nature of the human Ab response to DENV infection.
Much of our knowledge of this response has come from studies
using polyclonal sera from naturally infected patients. For in-
stance, using Ab depletion experiments, we previously demon-
strated that EDIII-binding Abs account for only a small fraction of
the anti-DENV binding and neutralization activity of immune
serum (11). Crill et al. confirmed that serotype-specific DIII Abs
formed a very small proportion of the polyclonal response; how-
ever, these investigators detected a difference in DENV neutral-
ization titers, albeit a small one, in the absence of these Abs (12).
Studies of a recombinant DENV3 (rDENV3/4) strain containing a
transplanted DENV4 E glycoprotein domain I/II (EDI/II) hinge
revealed that hinge transplantation led to a gain of sensitivity to
neutralization by DENV4 primary immune sera and a loss of neu-
tralization by DENV3 primary immune sera (13). Also, we re-
cently reported studies using human MAbs that support the
importance of the hinge region as a critical determinant of type-
specific neutralization activity directed to hinge regions from
wild-type (14) or recombinant hinge-transplanted (13) viruses.
Understanding the fine specificity of the human B cell response
to DENV requires the isolation of human MAbs, which have been
difficult to generate in the past. In the last several years, however,
we and others have isolated panels of naturally occurring human
MAbs which suggest that the human response targets both the E
and prM proteins and is made up largely of serotype-cross-reac-
tive and weakly neutralizing Abs (14–18). Only a very small per-
centage of Abs isolated to date that are directed against surface-
exposed epitopes are serotype specific, and the isolation of potent
neutralizing human MAbs (those neutralizing DENV at concen-
trations of 0.5 g/ml) is rare. The reasons for the difficulty in
isolating potent neutralizing human MAbs are several but include
the low frequency of such B cell clones in the human response and
the complex structural nature of the epitopes recognized, which is
difficult to recapitulate in laboratory protein reagents. DENV im-
mune serum depletion studies have shown that the Abs responsi-
ble for serum neutralizing activity following primary DENV infec-
tion target complex epitopes that exist in a correct conformational
state only on the virion particle, not on recombinant soluble forms
of E protein (11, 14). The structure of a virion-only-binding Ab in
complex with DENV1 was determined recently using cryo-elec-
tron microscopy, and this also revealed that the configuration of
antigenic regions of E protein in particles differs from that of
soluble E protein (19, 20). These observations raise the concern
that studies using recombinant E protein to isolate human B cells
for study may bias against the isolation of neutralizing Abs that
recognize antigens that are presented best in the context of viral
particles.
Our goal here was to develop a screening strategy to identify
and isolate very potent DENV-neutralizing human MAbs directed
to conformation-dependent E protein antigenic sites. We sought
to overcome the obstacle of the low frequency of circulating hu-
man B cells specifying high-potency Abs and the problem of con-
formational complexity of DENV neutralizing determinants. We
used a high-efficiency B cell transformation protocol to generate
thousands of human B cell lines from immune donors, screened
secreted Abs for binding to live DENV, and then used a secondary
screen to identify functional Abs by using a high-throughput, flow
cytometry-based neutralization assay with live DENV. Cell lines
secreting Abs that bound to live virus in immunoassay and neu-
tralized live virus in vitro were then fused to make hybridomas,
resulting in MAb-secreting clones. Using this new screening strat-
egy, we identified a large panel of human MAbs that were enriched
for potent neutralizing human MAbs and then performed detailed
characterization of these MAbs. Analysis of binding patterns of the
resulting DENV-neutralizing MAbs allowed us to define novel
recognition groups of epitopes that were associated with unique
patterns of fine specificity and neutralization and enhancing ac-
tivities.
MATERIALS AND METHODS
Human subjects and peripheral blood cell isolation. We identified a
panel of subjects in North Carolina and Tennessee who had acquired
DENV infection naturally by screening volunteers with suspected expo-
sure during past travel to regions where DENV is endemic. Subjects were
confirmed to have had DENV infection by testing their sera for the pres-
ence of Abs that neutralized one or more of the DENV serotypes. Periph-
eral blood mononuclear cells (PBMCs) were isolated by density gradient
separation on Ficoll. The cells were cryopreserved immediately and stored
in liquid nitrogen until study. The protocol for recruiting and collecting
blood samples from subjects was approved by the Institutional Review
Boards of the University of North Carolina at Chapel Hill and the Van-
derbilt University Medical Center.
Viruses and recombinant proteins. DENV1 (American genotype)
WestPac-74, DENV1 (Asian genotype) Philippines 2004, DENV2 (Asian
genotype) S-16803, DENV3 (American genotype) Nicaragua 1998,
DENV3 (Asian genotype) CH-53489, DENV3 (Asian genotype) Thailand
1974, and DENV4 (American genotype) TVP-376, provided by Robert
Putnak (Walter Reed Army Institute of Research, Silver Spring, MD),
were used in the present study for both binding enzyme-linked immu-
nosorbent assays (ELISAs) and neutralization assays. Infected cell culture
monolayer supernatants containing live DENV for use in virus-capture
ELISA were prepared in C6/36 mosquito cell monolayers grown in com-
plete minimal essential medium (MEM) (Gibco).
Recombinant proteins representing fragments of the E or prM pro-
tein, prepared as previously described (21), were used to determine anti-
gens and domains recognized by human MAbs. Fragments included the
full ectodomain of the E protein (which represents 80% of the E protein;
commonly referred to as E80 and here designated “rE”), a recombinant
fragment containing domains I and II (rEDI/II), and a recombinant frag-
ment containing domain III (rEDIII). cDNAs encoding recombinant
DENV proteins were constructed using the sequences of the above-de-
scribed strains. Sequence optimization, gene synthesis, and molecular
cloning of all recombinant DENV protein constructs for expression in
insect cells by use of a baculovirus vector were performed by GenScript
USA Inc. Protein production and purification were described previously
(21).
Generation of human hybridomas. Previously cryopreserved sam-
ples were thawed rapidly in a 37°C water bath and washed prior to trans-
formation with Epstein-Barr virus (EBV) in the presence of CpG, a Chk2
inhibitor drug, and cyclosporine, as described previously (15). Cultures
were incubated at 37°C with 5% CO2 for 10 days prior to screening for
virus-specific cell lines by ELISA. Cells from wells with supernatants re-
acting in an ELISA with captured live DENV were then expanded prior to
screening by flow cytometric neutralization assay (see below) and cytofu-
sion with HMMA2.5 nonsecreting myeloma cells, as previously described
Smith et al.
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(15). Following cytofusion, hybridomas were selected by growth in HAT
medium containing ouabain and biologically cloned.
MAb production and purification. Wells containing hybridoma cells
producing DENV-specific Abs were cloned biologically by three rounds of
limiting dilution plating or by use of a ClonePix device (Molecular De-
vices) per the manufacturer’s recommendations. Once clonality was
achieved, each hybridoma was expanded until 50% confluent in 75-cm2
flasks. For Ab expression, the cells in 75-cm2 flasks were collected with a
cell scraper; the hybridomas were washed in serum-free medium
(Gibco Hybridoma-SFM from Invitrogen) and split equally among
four 225-cm2 flasks (Corning) containing 250 ml serum-free medium.
Flasks were incubated for 21 days before the medium was clarified by
centrifugation and sterile filtered (0.2 m). Abs were purified from
clarified medium by protein G chromatography (protein G HP col-
umns; GE Life Sciences).
Virus-capture and recombinant protein-capture ELISAs. For virus-
capture ELISA, purified mouse MAb 4G2, prepared in carbonate binding
buffer, was used to coat ELISA plates (Nunc) and incubated at 4°C over-
night. After blocking for 1 h, plates were washed 5 times with phosphate-
buffered saline (PBS), and 50 l of live-DENV-containing culture super-
natant from infected C6/36 cell culture monolayers was added. Plates then
were washed 10 times with PBS, and 10 l of B cell culture supernatant
(during screening) or 5 l of purified human MAb at 1 g/l (during
characterization of clones) was added to 25 l/well of blocking solution.
Plates were incubated at room temperature for 1 h prior to washing 5
times with PBS. A secondary Ab conjugated to alkaline phosphatase (goat
anti-human Fc; Meridian Life Science) was applied at a 1:5,000 dilution in
blocking solution (25 l/well), and plates were again incubated at room
temperature for 1 h. Following repeat PBS washing 5 times, phosphatase
substrate solution (1 mg/ml phosphatase substrate in 1 M Tris amino-
methane; Sigma) was added at 25 l/well, and plates were incubated at
room temperature for 2 h before reading of the optical density at 405 nm
on a Biotek plate reader.
To define the binding domains of purified MAbs, we used ELISA bind-
ing to DENV protein fragments. Recombinant E or prM protein con-
structs fused to the Strep-tag II epitope were expressed using a baculovirus
vector and insect cells. Mouse anti-Strep-tag II MAb (StrepMAB-Immo;
IBA 2-1517-001) prepared in carbonate binding buffer was used to coat
ELISA plates (Nunc) and incubated at 4°C overnight. After blocking for 1
h, plates were washed 5 times with PBS, and 50 l of culture supernatant
from insect cells was inoculated with a baculovirus expressing a prM or E
recombinant protein fragment construct. Plates were then washed 10
times with PBS, and 5 l of purified human monoclonal Ab (1 g/l) was
added to 25 l/well of blocking solution. All other steps were performed as
described above for the virus-capture ELISA.
Competition assays. An Octet Red instrument (ForteBio) for biolayer
interferometry was used for competition binding studies to determine
which Abs bound to common major antigenic sites. For DENV1, we used
live virus as antigen; for DENV2, we used recombinant E protein. For
competition assays using whole DENV1 virions, purified biotinylated
mouse anti-DENV prM MAb 2H2 was loaded onto streptavidin tips
(ForteBio). A suspension of live DENV1 WestPac-74 was prepared by
pelleting virus from 250 ml of sterile-filtered supernatant from infected
C6/36 cell culture monolayers by ultracentrifugation for 12 h. The pellet
containing crude virion particles was then suspended in 5 ml PBS and
used for capture on biosensor tips coated with MAb 2H2. After a wash
step, the first anti-DENV MAb was added to saturation, followed imme-
diately by application of the second MAb to assess whether binding of the
first MAb interfered with binding of the second. For DENV2 recombinant
E protein competition assays, purified mouse anti-Strep-tag II MAb
(StrepMAB-Immo; IBA 2-1517-001) was loaded onto anti-mouse IgG Fc
capture tips (ForteBio) in order to capture the epitope-tagged recombi-
nant protein. We added a soluble form of recombinant E protein from
DENV2, designated rE (containing the extracellular domain, which is
about 80% of the E protein sequence), that was generated previously (18).
After a wash step, the first anti-dengue virus MAb was added. Without
washing, the second Ab was then added and binding assessed. We defined
competition for binding to the same antigenic site as a reduction of max-
imum binding of the second Ab to 25% of its binding in the absence of
the first Ab. When maximum binding of the second Ab was 75% of its
binding in the absence of the first Ab, we interpreted this finding as indi-
cating a lack of competition. All Ab competition experiments resulted in
maximum binding values for the second Ab that were 25% or 75%
compared to maximum binding without competition (i.e., there were no
ambiguous results due to intermediate levels of competition).
DENV Western blotting. Live DENV in infected cell culture superna-
tants was concentrated by ultracentrifugation and then loaded into a 4 to
12% SDS-PAGE gel run under denaturing, nonreducing conditions. After
transfer, the nitrocellulose membrane was probed with the purified hu-
man MAb in question (diluted 1:1,000) for 1 h at 37°C. The membrane
was washed with PBS plus Tween 20 (PBST) 3 times and then incubated
with alkaline phosphatase-conjugated goat anti-human Fc secondary Ab
(Meridian Life Science) for 1 h at 37°C prior to washing and development
using 5-bromo-4-chloro-3-indolylphosphate–nitroblue tetrazolium
(BCIP/NBT) chromogenic substrate (Invitrogen).
Neutralization assay. The neutralizing potency of MAbs was mea-
sured using a flow cytometry-based 96-well neutralization assay with ei-
ther Vero cells or a U937 human monocytic cell line stably transfected
with DC-SIGN, as previously described (22, 23).
ADE assay. The ability of Abs to enhance DENV infection was mea-
sured using U937 cells that had not been engineered to express DC-SIGN.
In the absence of the virus attachment factor, these Fc receptor-bearing
cells are susceptible to infection only in the presence of DENV-specific
Abs. The assay was performed as previously described in detail (15). ADE
activity was expressed as the fold enhancement of infected cells in the
DENV-specific Ab-treated sample compared to the sample treated with a
control Ab.
RESULTS
Frequencies of DENV-reactive B cells in subjects following
DENV infection. We selected three DENV-immune subjects for
our study: one following primary DENV2 infection, one following
primary DENV3 infection, and one following secondary infec-
tion. Serum neutralization titers specific to the four DENV sero-
types were used to define whether the subjects had a primary or
secondary infection (Table 1). PBMCs were obtained and studied
1 to 9 years following resolution of the infection. PBMC samples
were transformed, and transformed B cell culture supernatants
were first screened for binding to live DENV in virus-capture
ELISA. Based on the number of positive wells and the number of
lymphocytes tested (determined by average colony counts in
transformed wells), the frequency of DENV-specific B cells in cir-
culation was estimated for each subject. The frequencies of
DENV-specific B cells were determined to be similar between the
three DENV-immune samples: between 1.4 and 1.8 per thousand
transformable B cells (Table 1). In a separate experiment, addi-
tional screening was performed on EBV-transformed B cell cul-
tures from donor 1 (previously exposed to secondary DENV in-
fection), using recombinant E protein from each DENV serotype
(Fig. 1). We detected the presence of B cell lines secreting sero-
type-specific Abs to DENV1 or DENV3 but not to DENV2 or
DENV4, which is suggestive of previous infections with the former
two serotypes. This strategy for determining the infecting sero-
types following secondary infection has not been described previ-
ously.
Secondary screening of live-DENV-reactive B cell cultures by
use of a flow cytometric neutralization assay to enrich for B cell
lines secreting neutralizing Abs. Previous studies have demon-
Neutralizing Groups of Dengue Virus MAbs
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strated that most DENV-specific memory B cells secrete serotype-
cross-reactive, poorly neutralizing Abs and that only a minor frac-
tion (5% of DENV-specific B cells) secrete strongly neutralizing
Abs associated with long-term protection (14, 15, 18). We used a
flow cytometry-based neutralization assay (22, 23) as a secondary
screen to identify B cells producing rare strongly neutralizing Abs
(Fig. 2). In each case, the cultures exhibiting the highest neutral-
ization capacity were directed against the serotype(s) responsible
for the donor’s infection according to serology (Fig. 2). As ex-
pected, a very large percentage of cultures from each donor
mediated 50% neutralization in the assay. In fact, many lines
had no detectable neutralizing capacity or caused an apparent
enhancement of DENV infection in the assay. We selected for
cytofusion the top 30 to 40% of DENV-reactive B cell lines,
based on percent neutralizing activity against the serotype(s) of
the infecting strain(s) in the donor, as indicated in the boxed
areas in Fig. 2.
Distinct groups of neutralizing MAbs exhibiting diverse
binding and functional properties. DENV-reactive B cell cul-
tures selected based on live virus binding plus the virus neutral-
ization screen were processed by cytofusion with a myeloma cell
partner to generate human hybridoma cells stably secreting fully
human anti-DENV MAbs. A total of 50 human MAbs were gen-















































































































































































































































































































































































































































































FIG 1 DENV rE protein-reactive Ab responses reveal that the two infecting
serotypes for donor 1 (with secondary infection) were DENV1 and DENV3.
Supernatants from EBV-transformed B cell cultures from donor 1 were
screened for binding to rE protein from each DENV serotype. A total of 249
cultures were determined to react with one or more DENV rE proteins in
ELISA. Serotype cross-reactivity profiles are shown for 81/249 (33%) cultures
that bound DENV1 rE protein (A), 50/249 (20%) that bound DENV2 rE
protein (B), 72/249 (29%) that bound DENV3 rE protein (C), and 46/249
(18%) that bound DENV4 rE protein (D). Serotype-specific, binds only one
serotype; subcomplex-reactive, binds more than one but fewer than four sero-
types; complex-reactive, binds all four serotypes.
Smith et al.
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nors, with a significant number of clones having strong neutraliz-
ing potency (see Table S1 in the supplemental material). Detailed
characterization revealed that many strongly neutralizing and se-
rotype-specific MAbs were identified in this panel. Still, a signifi-
cant proportion of the MAbs generated were DENV complex re-
active, displayed weak or no neutralizing potency, and exhibited
significant ADE capacity in cell culture.
While we were characterizing these MAbs, a number of inter-
esting different neutralizing classes of Abs emerged (which we
designated groups A through F), exhibiting diverse binding and
functional properties (Table 2). Groups of MAbs that target prM
or different regions of the E protein could be distinguished. We
used the following definitions to describe the breadth of Abs for
the four serotypes: serotype specific, binds only one serotype;
DENV subcomplex reactive, binds more than one but fewer than
four serotypes; and DENV complex reactive, binds all four sero-
types. The diverse characteristics displayed by these groups of
MAbs represent binding to various epitopes, and possibly differ-
ent mechanisms of neutralization. For example, in one case, for
the group C MAb 1F4, which possesses potent serotype 1-specific
neutralizing activity, the Ab was found to target an epitope present
only on the intact viral particle (14, 20). As can be seen in Fig. 3A,
MAb 1F4 exhibited strong DENV1-specific neutralization po-
tency (50% effective concentration [EC50] of 0.1 g/ml), without
the ability to bind or enhance infectivity of other serotypes. An-
other group of potently neutralizing serotype-specific Abs is ex-
emplified by 3F9 (group B) (Fig. 3B). MAb 3F9 is serotype specific
in binding and neutralization (in this case, to DENV2; EC50 
0.03 g/ml), but unlike 1F4, which binds only to virions, 3F9
binds to recombinant E protein and targets EDIII. Another group
of strongly neutralizing MAbs, designated group D, are DENV
complex reactive in binding but serotype specific in neutraliza-
tion. MAb 4L5, isolated from donor 1, who had a history of sec-
ondary infection, bound viruses of all four DENV serotypes
equally in ELISA, but it neutralized only DENV1. One interesting
DENV complex-reactive Ab (MAb 1I12) bound the prM protein
and strongly neutralized DENV3, which is an unexpected prop-
erty for a prM-specific Ab.
The group of neutralizing Abs that contained the most mem-
TABLE 2 Patterns of binding to recombinant proteins and functional activities of DENV-reactive neutralizing MAbsa
Reactivity mAb group  mAb Donor 
Binding reactivity Functional activity  
 





A 1L12 3 + - - -     .40 - D2     /AgE         /N2++          /E- 
B 3F9 3 + + - -     .03 - D
2     /AgEDIII  /N2+++       /E- 
4J23 3 + + - -  4.20 - D2     /AgEDIII  /N2+            /E- 
C 1F4 1 - - - -     .10 - D1     /AgV         /N1++         /E- 
Cross-
reactive 
D 4L5 1 + - - -  1.30 - D1-4 /AgE         /N1+            /E- 
E 
1M7 2 + - + -    .02 - D1-4 /AgEDI-II/N2,3,4+++  /E- 
1C18 1 + - + -    .20 - D1-4 /AgEDI-II/N1++          /E- 
4E8 1 + - + -    .20 - D1-4 /AgEDI-II/N1,2++,3+  /E- 
5C8 1 + - + -  1.00 - D1-4 /AgEDI-II/N1-4+         /E- 
1L6 1 + - + -  1.10 - D1-4 /AgEDI-II/N1,3+         /E- 
3B4 1 + - + -  1.30 - D1-4 /AgEDI-II/N1-4+         /E- 
1N8 1 + - + -  4.10 - D1-4 /AgEDI-II/N1,2+         /E- 
F 1I12 1 - - - +    .20 + D1-4 /AgEDI-II/N3++          /E3,4+ 
a *, lowest concentration at which 50% neutralization (Neut) occurred in flow cytometry-based neutralization assay against any of 4 serotypes. #, presence of
25-fold Ab-dependent enhancement for any of the 4 serotypes tested at 1 g/ml. **, the key to phenotypes is as follows: D, dengue virus binding [the
superscript indicates the serotype(s) of virus bound in whole-virus-capture ELISA]; Ag, antigen binding pattern, i.e., which recombinant E protein domain
antigen, if any, was bound in ELISA (E  envelope, V  virion-only binding, DI-II  domain I-II fusion protein, and DIII  domain III); N, neutralization
(the superscript indicates which of the 4 serotypes of virus were neutralized in the flow cytometric neutralization assay) (, , and  indicate
concentrations where 50% of virus was neutralized, in ranges of 1 to 5, 0.1 to 0.9, and 0.1 g/ml, respectively); and E, enhancement, i.e., the serotype(s) of







FIG 2 Secondary screening of live-DENV-reactive B cell cultures in a flow
cytometric neutralization assay using U937 cells expressing DC-SIGN. The
percent neutralization mediated by Abs in supernatants of EBV-transformed B
cell cultures from three donors is shown for viruses of the four DENV sero-
types. We tested 178 supernatants from donor 1 (previous secondary infection
with DENV1 and DENV3), 90 supernatants from donor 2 (primary DENV3
infection), and 116 supernatants from donor 3 (primary DENV2 infection).
Individual B cell lines chosen for cytofusion and generation of hybridomas are
indicated by symbols within black boxes and are also highlighted in red to
show their distribution of neutralizing activity for all serotypes. For donor 1,
we selected lines with highest activity toward DENV1 or DENV3; for donor 2,
we selected those with highest activity toward DENV3; and for donor 3, we
chose those with highest activity toward DENV2. The concentrations of indi-
vidual MAbs in this screening assay of cultures containing multiple B cell
clones were unknown; however, in some cases, a high level of activity in this
screen predicted a high potency of the identified clone. For example, the high-
est point of neutralization in donor 1 clones neutralizing DENV1, which neu-
tralized DENV1 at a 95% level, was later isolated as the potent MAb 1F4.
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bers (group E) was DENV complex reactive in binding, and these
Abs neutralized viruses of more than one DENV serotype. MAb
1M7, for example, bound and strongly neutralized viruses of
DENV serotypes 1 through 4 in cells, with EC50s of 0.55, 0.14, 0.06,
and 0.60 g/ml, respectively (Fig. 3C). Abs in two of the three
cross-reactive groups, groups D and E, targeted the EDI/II region.
Abs in these two major groups were quite variable in their neu-
tralization potency. For example, MAb 1M7 was strongly neutral-
izing (EC50 of 0.02 g/ml), while 1N8 was only weakly neutraliz-
ing (EC50 of 4.1 g/ml), representing at least a 200-fold range of
activity. Potent MAbs (EC50s of 0.5 g/ml) were isolated from
both primary and secondary cases, at similar frequencies (3/23
clones from primary cases and 4/27 clones from secondary cases).
Binding and functional properties of groups of nonneutral-
izing and enhancing MAbs. Despite our strategy to enrich the
number of neutralizing MAbs generated, characterization of the
resulting MAbs also revealed several different classes of nonneu-
tralizing MAbs (designated groups G through K), which were
grouped based on binding and functional properties (Table 3).
Many Abs identified in this study (groups H to K) were DENV
complex reactive and had little or no neutralizing or enhancement
capacity. These groups of MAbs exhibited similar functional
properties, but they targeted different sites on the virus. The group
of nonneutralizing Abs that contained the most members (group
I) was DENV complex reactive in binding and targeted EDI/II.
Group K MAbs were complex reactive in binding but bound to
prM. Several of these Abs exhibited remarkable ADE activity. For
example, MAb 3I18 from group I and MAb 5E15 from group K
were potent at enhancing infection in vitro, increasing infectivity
by 66- and 61-fold, respectively.
Potent serotype-specific MAbs display little enhancement
potential. Many of the most potent neutralizing Abs identified
here were serotype specific in their binding and neutralization
(groups A to C) (Table 2; see Table S1 in the supplemental mate-
rial). When these were tested for the ability to enhance DENV
infection in cell culture at 1.0 g/ml, little activity was detected.
We also tested representative antibodies from different groups in
a broad range of dilutions in the ADE assay (clones indicated with
yellow highlighting in Table S1; data not shown). We found that
one of the cross-neutralizing antibodies (1M7) of group E that was
not identified previously as possessing ADE activity did show en-
hancement capability at a very low concentration (0.008 g/ml).
The neutralization potency of MAbs in groups A through D was
tested in several cell lines, since activity is known to vary in differ-
ing lines (Table 4). We also tested the neutralization activity
against viruses of Asian versus American genotypes for represen-
tative clones, since two of the donors were infected in the Ameri-
cas (data not shown). In most cases, the activities were compara-
ble, although the activity appeared to be higher for the 1M7 MAb
against the DENV3 strain from Nicaragua, the country where the
relevant donor was infected.
Epitope mapping using competition assays. We further char-
acterized our panel of MAbs by determining competition binding
groups. Using a real-time biosensor, we performed competitive
binding studies with representative full-length MAbs to intact
DENV1 particles or recombinant soluble DENV2 rE protein. As
can be seen in Fig. 4, top panel, representative MAbs from the
panel segregated into three principal competition groups when
binding to the intact DENV1 particles. Inclusion of MAbs with
known binding domains in the assay allowed us to attribute these
groups to prM, fusion loop, and DI/II hinge region specificity. In
testing for competition using DENV2 recombinant E protein, two
main competition groups emerged (Fig. 4, bottom panel), includ-
ing a large group recognizing the fusion loop region. Representa-
tive MAbs from the complex-reactive group E (neutralizing) or
group I (nonneutralizing) MAbs competed for the same major
antigenic site. MAb 5E15, which is representative of group K,
bound to prM protein and was found to compete with the previ-
ously isolated human prM-binding Ab 4F8, which was included
for comparative purposes.
DENV complex-reactive MAbs target a region of EDII
around the fusion loop. The largest groups of neutralizing and
nonneutralizing Abs identified in our studies were groups E and I.
Group E MAbs are DENV complex reactive and exhibit neutral-
izing activity toward viruses of more than one DENV serotype. We




FIG 3 Neutralization profiles of potent serotype-specific and complex-reac-
tive human MAbs in U937 cells expressing DC-SIGN. Neutralization curves
are shown for the following representative potent, serotype-specific human
MAbs: DENV1-specific MAb 1F4 (A), DENV2-specific MAb 3F9 (B), and
serotype-cross-neutralizing human MAb 1M7 (C). Neutralization is shown
across a series of concentrations (in g/ml). EC50s were determined for MAb
1F4 (DENV1 EC50  0.1 g/ml), MAb 3F9 (DENV2 EC50  0.03 g/ml), and
MAb 1M7 (DENV1 EC50  0.55 g/ml, DENV2 EC50  0.14 g/ml, DENV3
EC50  0.06 g/ml, and DENV4 EC50  0.60 g/ml).
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performed competitive binding studies, using either intact DENV1
particles or rE protein, with the previously isolated fusion loop-
binding human MAb 3H4. Representative DENV complex-reac-
tive MAbs from groups D, E, and I, each of which binds to rE
protein, competed for binding with the human fusion loop-bind-
ing MAb 3H4. Competition of these MAbs was observed using
either DENV1 particles (Fig. 4, top panel) or rE protein (Fig. 4,
bottom panel), suggesting that MAbs in groups D, E, and I target
similar antigenic sites focused on or near the fusion loop.
DISCUSSION
This study describes the isolation and characterization of 50 hu-
man MAbs to DENV by employment of a unique screening strat-
egy to enrich MAbs possessing neutralizing activity. The rationale
for the strategy was to focus the MAb isolation on Abs that recog-
nized epitopes present in live virus particles, using a two-step
screening strategy based on live virus binding and neutralization
of wild-type virus in vitro. Supernatants from a total of 384 differ-
ent live-DENV-reactive B cell cultures from three donors were
assayed for neutralization potency. Cultures with Abs that bound
to live virus and that possessed the highest degree of neutralizing
potency were then selected for electrical cytofusion to generate
human hybridomas, resulting in 50 new human MAbs. Charac-
terization of the final purified MAbs resulted in the identification
of a large number of diverse groups of Abs exhibiting different
unique neutralization potencies, binding locations, and ADE ac-
tivities.
In the process of generating human MAbs, we expanded
DENV-reactive B cell cultures to allow for screening in neutraliza-
tion assays. During this stage, we were able to estimate the fre-
quency of circulating B cells that were reactive to DENV in the
donor blood samples. Each of the donors tested had a remote
history of DENV infection, ranging from 1 to 9 years prior. De-
spite the differences in serotype, location, and number of years
since infection, the estimated frequencies of DENV-reactive cir-
culating B cells were remarkably similar, at about 1 to 2 per thou-
TABLE 3 Pattern of binding to recombinant proteins and functional activities of DENV-reactive nonneutralizing MAbsa
Reactivity Group label mAb Donor 
Binding reactivity Functional activity 
D/Ag/N/E Phenotype** 




specific  G 2F6 1 + + - - >5 - D
1    /AgEDIII    /N- /E- 
Cross-
reactive 
H 1K8 2 + + - - >5 - D1-4 /AgEDIII   /N- /E- 
I 
2L2 2 + - + - >5 - D1-4 /AgEDI-II /N- /E- 
1L4 1 + - + - >5 - D1-4 /AgEDI-II /N- /E- 
3D18 1 + - + - >5 - D1-4 /AgEDI-II /N- /E- 
1H20 1 + - + - >5 - D1-4 /AgEDI-II /N- /E- 
1K16 1 + - + - >5 - D1-4 /AgEDI-II /N- /E- 
1I16 1 + - + - >5 - D1-4 /AgEDI-II /N- /E- 
3G5 1 + - + - >5 - D1-4 /AgEDI-II /N- /E- 
3I18 1 + - + - >5 + D1-4 /AgEDI-II  /N- /E2++,3+ 
J 3E8 2 + - - - >5 + D1-4 /AgEDI-II  /N- /E3++ 
K 
1E16 2 - - - + >5 - D1-4 /AgprM     /N- /E- 
1B22 1 - - - + >5 - D1-4 /AgprM     /N- /E- 
5E15 1 - - - + >5 + D1-4 /AgprM     /N- /E3++ 
6B16 3 - - - + >5 + D1-4 /AgprM     /N- /E1++,3++ 
a *, 50% neutralization was not detected at any concentration up to 5 g/ml in flow cytometry-based neutralization assays against any of the 4 serotypes. #,
presence of 25-fold Ab-dependent enhancement for any of the 4 serotypes tested at 1 g/ml. **, the key to phenotypes is as follows: D, dengue virus binding
[the superscript indicates the serotype(s) of virus bound in whole-virus-capture ELISA]; Ag, antigen binding pattern, i.e., which recombinant E protein
domain antigen, if any, was bound in ELISA (E  envelope protein, prM  premembrane protein, DI-II  domain I-II fusion protein, and DIII  domain
III); N, neutralization; and E, enhancement, i.e., the serotype(s) of virus enhanced in a flow cytometric ADE assay at 1.0 g/ml (, 25-fold enhancement; ,
25- to 49-fold enhancement; , 50- to 100-fold enhancement).




U937 cells expressing DC-SIGN Vero-81 cells
DENV1 DENV2 DENV3 DENV4 DENV1 DENV2 DENV3 DENV4
DENV1 1F4 0.1    0.02   
4L5 1.3    0.05   
DENV2 1L12  0.4    0.05  
3F9  0.03    0.003  
4J23  4.0    0.08  
a EC50s of 1.0 to 10.0 g/ml are shown. EC50s of 1.0 g/ml are shown in bold, and EC50s of 0.1 g/ml are shown in bold italics. , neutralization was not detected when the
MAb was tested at concentrations as high as 10 g/ml.
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sand. This finding suggests that there may be a typical long-term
set point frequency of B cells in the circulating peripheral blood
memory B cell pool following DENV infection.
By testing our B cell culture supernatants for binding to all four
DENV serotypes, we were able to determine the frequencies of
complex-reactive or serotype-specific B cells. This information
allowed us to determine the virus serotypes likely responsible for
remote secondary infection in a donor with more than one prior
infection, a method not previously described. Donor 1 demon-
strated the typical serum titers seen in an individual following
secondary DENV infection, with elevated serum titers to all four
serotypes. Using the B cell transformation and culture technique,
we were able to determine that among the many clones detected,
this donor possessed some that were derived from DENV1 or
DENV3 (but not DENV2 or DENV4) serotype-specific B cells,
suggesting prior exposure to viruses of these two serotypes.
Screening of a large number of live-DENV-reactive B cell cul-
ture supernatants for neutralization potency clearly demonstrated
the consistency of the pattern of induction of serotype-cross-re-
active and weakly or nonneutralizing Abs that has been observed
previously following DENV infection. For the donor with prior
secondary infection studied here, more than 98% of B cell line
supernatants with DENV-specific Abs showed 70% neutraliza-
tion activity. Interestingly, a large percentage of live-DENV-reac-
tive unpurified supernatants tested exhibited significantly nega-
tive values in the neutralization assay (meaning a higher
percentage of inoculated cells were infected than the case in the
absence of Ab). It should be noted that at the screening stage, as
shown in Fig. 2, the concentration of a particular live-DENV-
reactive MAb could not be determined in the culture supernatant
from EBV-transformed B cell lines containing multiple trans-
formed colonies (i.e., there were multiple transformed B cell
clones in each well, only one of which was likely to be DENV
specific). Therefore, the exact neutralization or enhancing po-
tency could not be established for the screening supernatants, in
contrast to the data with purified IgG from cloned hybridoma cells
shown in later experiments.
To further study the neutralizing Ab response to DENV infec-
tion, B cell cultures possessing the highest potencies in our neu-
tralization screening assay were selected for the generation of hu-
man hybridomas. Ultimately, 50 human hybridomas were
generated, with isolation of a relatively large number of those se-
creting MAbs with strong neutralizing potency. Since the initial
screen was performed with unpurified supernatants from EBV-
transformed B cell lines, it was not surprising that some of the
resulting clones did not possess neutralizing activity when tested
as purified immunoglobulins. Analysis of this large Ab panel dem-
onstrated that both neutralizing and nonneutralizing MAbs seg-
regated into distinct phenotypic groups based on functional char-
acteristics. Groups of serotype-specific and complex-reactive
MAbs were characterized further. Interestingly, the most potent
serotype-specific MAbs bound either to EDIII or to complex
epitopes found only on the intact viral particle. Competition stud-
ies between groups of serotype-specific neutralizing MAbs re-
vealed the presence of Abs to prM, the fusion loop, the DI/II hinge,
and DIII. The most potent Ab that we isolated here, MAb 3F9,
targeted EDIII, with a neutralizing activity of 3 ng/ml in Vero-81
cells. This finding was interesting because most human neutraliz-
ing Abs in polyclonal sera do not recognize DIII, and many neu-
tralizing Abs in mice do recognize DIII.
Determining the epitopes recognized by potently neutralizing
Abs induced in humans by natural infection may be one of the best
tools that we have for understanding the determinants of human
protection. Sites that induce ultrapotent neutralizing activity
should be the focus of future rational DENV vaccine design. Based
on the information provided here, we propose two distinct but
compatible strategies for rational design of an effective DENV
vaccine. One strategy would make use of the low potential for
disease enhancement intrinsic to the induction of neutralizing
Abs that recognize viruses of only one serotype (serotype-specific
Abs). In this case, antigenic preparations incorporating epitopes
with type-specific determinants could be developed to induce po-
tent protection, without the generation of unwanted, potentially
dangerous cross-reactive and nonneutralizing Abs. We designated
this scheme a “four-by-one” vaccination plan (a mix of four vac-
cine candidates, each targeting one serotype). A second strategy
would be to focus on synthesis of immunogens that possess cross-
reactive antigenic determinants, but only incorporating those
finely mapped features of epitopes that induce ultrapotent Abs
that neutralize viruses of all four DENV serotypes. This scheme we
designate a “one-by-four” vaccination strategy (one immunogen
targeting all four serotypes). In this case, the response would be
across serotypes, but the Abs elicited should narrowly target po-
tent neutralizing epitopes, reducing the chance of enhancement at
physiologic Ab concentrations. Of course, one might consider a
five-valent strategy in which the “four-by-one” and “one-by-four”
immunogens are combined, with the goal of inducing both type-
FIG 4 Antibody competition groups for ELISA binding to DENV1 or DENV2
rE protein antigen. Underlined clone names indicate MAbs that bound to both
DENV1 and DENV2 and thus were tested in both assays. x, completion with
the same antibody (competition was detected in all cases); , binding of the
first antibody applied (listed in vertical column) reduced binding of the second
antibody applied (indicated in top row); o, competition was not detected. *,
MAb 4F8 was previously isolated and was included here as a control, since it
was shown previously to bind to the prM protein; **, MAb 3H4 was isolated
previously and was included here as a control, since it was previously shown to
bind to the fusion loop of E protein DI-II.
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specific and cross-reactive neutralizing Abs without induction of
cross-reactive nonneutralizing responses.
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